AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba (Japan).
The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other types of therapeutic proteins.
AGC Biologics currently provides mammalian protein process development and manufacturing services from its facilities in Bothell (USA), Berkeley (USA) and Copenhagen, Denmark as well as microbial process development and manufacturing services from its facilities in Heidelberg, Germany, Copenhagen, Denmark, and Chiba Japan. The Company will leverage its extensive experience and expertise with mammalian production systems to rapidly establish these services at its site in Japan.
AGC Biologics is a leading global Contract Development and Manufacturing Organization, with an extensive network of cGMP facilities in the US, Europe and Asia.